Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mann, J. F. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mann, J. F. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 453-454
© 2000 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Should the results of the HOPE study affect nephrological practice?

Johannes F. E. Mann, for the HOPE investigators

Schwabing Hospital, LMU, München, Germany

Correspondence and offprint requests to: Johannes Mann, MD, Krankenhaus Schwabing, LMU, D-80804 München, Germany. E-mail tbn02ab@mail.lrz-muenchen.de.

Which hypothesis was tested?

The renin–angiotensin system (RAS) is well known for its role in blood pressure and electrolyte and volume homeostasis. Experimental evidence from recent years linked the RAS with inflammatory processes; the stimulation of interstitial fibrosis and of mesangial sclerosis may be taken as examples in nephrology [1,2]. In a more general perspective, the RAS was shown experimentally to promote the initiation and progression of atherosclerosis by its pro-inflammatory and pro-coagulatory actions. In accordance with this notion, epidemiologial evidence associated activation of the RAS with a higher prevalence of . . . [Full Text of this Article]

What was done?

What was found?

How do the results affect patient management by the nephrologist?

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
B. Afzali, A. A. Haydar, K. Vinen, and D. J.A. Goldsmith
From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease
J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2161 - 2168.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B Afzali and D J A Goldsmith
Beneficial effects of statins on the kidney
J. Clin. Pathol., July 1, 2004; 57(7): 673 - 674.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Afzali, A. A. Haydar, K. Vinen, and D. J. A. Goldsmith
Beneficial effects of statins on the kidney: the evidence moves from mouse to man
Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1032 - 1036.
[Full Text] [PDF]